Released Jun 14, 2022, after the close
10-Q filed Jun 14, 2022, 45 days after period end · 0001654954-22-008332
Q2 2022 · 10-Q
Revenue$4.97M$4.97M −1.5% vs Q2 2021−1.0% vs Q1 2022
Net Income$240.03K$240.03K −0.1% vs Q2 2021−21.4% vs Q1 2022
EPS, diluted—
Gross Profit$1,215,906−5.8%
Operating Income$280,630+6.0%
Operating Cash Flow-$446,285N/M
Free Cash Flowderived-$450,646N/M
Margins · derived
Gross margin24.5%−1.1 pt vs Q2 2021
Operating margin5.6%+0.4 pt vs Q2 2021
Net margin4.8%+0.1 pt vs Q2 2021
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $4.97M | $5.04M | $5.65M | $5.15M |
| Net Income | $240.03K | $240.27K | $687.56K | $707.48K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR